<DOC>
	<DOCNO>NCT00701688</DOCNO>
	<brief_summary>Mucositis well-known complication autologous allogeneic hematopoietic stem cell transplantation ( HSCT ) . Many suffer disorder require total parental nutrition intravenous narcotic pain control . Palifermin ( Kepivance [ TM ] ) human keratinocyte growth factor produce recombinant DNA technology E. coli . Palifermin FDA-approved , commercially available pharmacologic agent manufacture Amgen . As keratinocyte growth factor receptor find within epithelium gastric mucosa , use palifermin proven decrease frequency duration severe mucositis adult study . Whereas appropriate dose regimen determine adult 60mcg/kg/day , dose palifermin establish pediatric setting . This initial pediatric study palifermin determine maximum tolerate dose , evaluate use agent three dose level , , , recommend adult dose . Non-hematologic , life-threatening NCI grade IV grade V toxicity definitely related administration palifermin first infusion day +6 HSCT ( post palifermin administration day +3 ) comprise safety endpoint study . The study design evaluate palifermin 3 dose level . The study population recipient either match family member donor match unrelated donor HSCT . The pharmacokinetics palifermin dose level describe help determine appropriate dose future study , evaluate efficacy</brief_summary>
	<brief_title>Dose Escalation Study Of Palifermin Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description>Secondary objective study include explore pharmacoeconomics palifermin particular patient population assessment inpatient day , intravenous nutrition , analgesia requirement within 100 day post-transplantation . We also explore research participant ' rate immune reconstitution , specifically T B-lymphocytes NK cell , within first year HSCT .</detailed_description>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<criteria>Age great equal 2 year less 18 year age . Diagnosis hematologic malignancy . Has receive prior autologous allogeneic HSCT . Is schedule receive either match family member MUD bone marrow stem cell graft St. Jude Children 's Research Hospital . A matched family member donor define sibling match 5 6 HLA locus another relate donor match 6 HLA locus . Is schedule receive myeloablative preparative regimen ( cyclophosphamide/TBI base ) prior infusion allogeneic graft . Cardiac shorten fraction great equal 25 % . Serum creatinine less twice upper limit normal age . Bilirubin le 3.0 mg/dl . Aspartate transaminase ( AST ) less 500 IU/ml . Alanine transaminase ( ALT ) less 500 IU/ml . Amylase less 1.5 time upper limit normal age . Lipase less 1.5 time upper limit normal age . Forced vital capacity ( FVC ) great equal 40 % predict value pulse oximetry great equal 92 % room air . No known hypersensitivity E coliderived protein palifermin . No active recent ( within 30 day prior enrollment ) gastrointestinal bleeding . No active recent ( within 30 day prior enrollment ) oral ulceration . No active fungal infection , bacteremia viremia within two week prior enrollment . Female pregnant ( negative serum urine pregnancy test within 14 day prior enrollment ) . Female lactating .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Mucositis , Oral</keyword>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>Allogeneic Transplantation</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Maximum Tolerated Dose</keyword>
</DOC>